Human immunodeficiency virus (HIV)-
Human antibodies to polysaccharides often manifest regoclonal, and their variable region heavy chains (V H ) are derived from V H 3 gene segments [3] . Similarly, human monostricted utilization of immunoglobulin gene elements [1] . Therefore, they are likely to be derived from limited, or oliclonal antibodies (MAbs) specific for the capsular polysaccharides of Cryptococcus neoformans and serotype 3 Strepgoclonal, subsets of antibody-producing B cell precursors that express only a few variable and constant gene segments. There tococcus pneumoniae are derived from V H 3 gene segments [4, 5] . Antibodies derived from V H 3 genes frequently bind to are seven human immunoglobulin heavy chain gene families, and the V H 3 gene family is the largest. The fact that B cells staphylococcal protein A (SpA) through an alternative binding site consisting of framework sequences of the antibody V H expressing V H 3 constitute almost 50% of the circulating repertoire has been shown to reflect selection [2] , and human anti- [6] . Further evidence for V H 3 usage by antibodies to capsular polysaccharides is provided by the fact that serum antibodies bodies specific for capsular polysaccharides of several encapsulated pathogens are derived from V H 3 genes [1] . However, the to cryptococcal and pneumococcal capsular polysaccharides of serotypes 3, 14, and 18 S. pneumoniae and C polysaccharide mechanism of antibody restriction is unknown. also bind SpA [4, 7, 8] . While SpA is regarded as a B cell Vaccine-elicited antibodies to Haemophilus influenzae type superantigen, the biologic significance and implications for b polyribosylribitol phosphate capsular polysaccharide are olihost-pathogen interactions of SpA binding to V H 3 antibodies is not known. Nevertheless, human immunodeficiency virus (HIV) gp120 is also a B cell superantigen that is restricted BSA; Sigma, St. Louis) and then incubated with 50 mg/mL cell (reviewed in [1] ). B cell dysfunction has been suggested to wall polysaccharide (CWPS; Statens Seruminstitut, Copenhagen) explain these phenomena [1, 11, 19] , although it is not known if for 1 h at 4ЊC before being used for ELISAs. The adequacy of the specific or generalized defects translate into decreased antibody absorption procedure was confirmed by comparing the binding of responses. Nevertheless, B cell defects, or status of the immuabsorbed and unabsorbed sera on a CWPS-coated plate, which noglobulin repertoire, may contribute to impaired antibody rerevealed a §80% reduction in the binding of adsorbed pre-and sponses to pneumococcal capsular polysaccharides. postvaccination samples to CWPS at serum dilutions of both 1:100 Growing rates of pneumococcal resistance to penicillin [20 antibodies from HIV-infected and HIV-uninfected subjects beogy). All alkaline phosphatase-labeled antibodies were used at a fore and after vaccination with a 23-valent pneumococcal polyconcentration of 1 mg/mL. saccharide vaccine (pneumococcal vaccine).
ELISAs. Unless otherwise stated, ELISA plates were prepared as follows: 96-well polystyrene plates (Costar; Corning Glass Works, Corning, NY) were coated for 3 h at room temperature
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with 10 mg/mL pneumococcal capsular polysaccharides (11.4 mg/ mL polysaccharide in the whole vaccine), blocked overnight at Sera. Studies were done with pre-and postvaccination sera 4ЊC with PBS-BSA, and washed four times with PBS containing from 10 HIV-uninfected and 10 HIV-infected volunteers who re-0.05% Tween 20 (Sigma) (PBS-T). The capsular polysaccharides ceived one intramuscular dose of the 23-valent pneumococcal used were the whole pneumococcal vaccine, Pneumovax 23 polysaccharide vaccine (Pneumovax 23; Merck, West Point, PA). for 1 h at 37ЊC with the serum samples. After incubation, the HIV-uninfected subjects ranged in age from 23 to 41 years. They plates were washed four times with PBS-T and incubated for 1 h were recruited for this study and vaccinated at the Albert Einstein at 37ЊC with secondary antibodies (see above). After incubation College of Medicine.
with the enzyme-linked antibodies used for detection (see above), The 10 HIV-infected study subjects ranged in age from 26 to the plates were washed and developed with p-nitrophenyl phos-61 years. They were recruited, enrolled, and vaccinated at the phate (Sigma). The absorbances of the wells were measured at Houston VA Medical Center. These subjects were selected for 405 nm with a Ceres 900 microplate reader (Biotek Instruments, this study because they represented a relatively immunocompetent Winooski, VT). The absorbance of wells that did not contain serum population of HIV-infected persons. The mean CD4 T cell counts was subtracted from each duplicate experimental well. All plates of the subjects were 395 { 185 cells/mL before vaccination and included a high-titer serum from a pneumococcal vaccine re-465 { 255 cells/mL after vaccination, and their geometric mean sponder as a positive control and wells that did not contain serum. virus loads were 1495 before vaccination and 1097 after vaccinaIsotypes of antibodies to pneumococcal polysaccharides. The tion. Virus loads were determined with a previously described titers of IgG and IgM to the capsular polysaccharides of serotype polymerase chain reaction-based technique used to determine the 4, 8, 14, and 23F pneumococci and the whole pneumococcal vacamount of retroviral RNA in plasma [23] . All subjects had been cine were determined by ELISA with plates coated as described receiving a stable antiretroviral regimen for at least 1 month.
above. The individual serotypes were selected because they cause Blood samples were obtained before and 28 days after vaccinadisease in both HIV-uninfected and HIV-infected persons [19] tion from both groups. Serum was separated from whole blood and have different immunogenicities [25] : Serotype 8 is highly samples by centrifugation and stored at 020ЊC. All of the serum immunogenic, serotypes 4 and 14 have intermediate immunogenicsamples studied had been obtained 3-6 months before use. All ity, and serotype 23 is poorly immunogenic. In addition, serotypes samples from both HIV-infected and HIV-uninfected subjects were 14 and 23F, which are also responsible for infections in the pediatheat-treated for 30 min at 56ЊC. The samples were subsequently ric age group, have manifested increased rates of penicillin resisdiluted 1:100 for end-point titer determinations and 1:50 for idiotype studies in PBS containing 1% bovine serum albumin (PBStance [26] . The whole vaccine was used to coat plates because it has been used by other groups to assess the pneumococcal vaccine infected and HIV-uninfected vaccinees were compared with the Sign test, a nonparametric test that uses the median as a measure responses of HIV-infected persons [13, 27] .
The plates were incubated with serial 3-fold dilutions of serum of central tendency. Overall responses to pneumococcal capsular polysaccharides expressing different idiotypic determinants were samples from the vaccinees beginning at a dilution of 1:100. After incubation, the plates were washed and incubated with alkaline determined by subtracting postvaccination from prevaccination values. Antibody responses were compared between groups (e.g., phosphatase-labeled goat anti-human IgG and IgM used at a concentration of 1 mg/mL, and antibody binding was detected as de-HIV-infected and HIV-uninfected) by the Mann-Whitney U test. This approach was used for between-group comparisons of the tailed above. The titers of antibodies to each individual capsular polysaccharide and to polysaccharides in the whole vaccine were change in antibody levels after vaccination because the levels of total immunoglobulin and/or prevaccine antibodies may not be determined from titration curves as follows: The background absorbance (that of the wells without serum) was subtracted from comparable between groups. P values were determined with a statistical software package (SPSS, Chicago), and values õ.05 each data point, the data were plotted on a semilog scale, the final data point after which the next data point decreased was defined were considered significant. as the end point, the absorbance of the end point was multiplied by 1.5, and the dilution corresponding to that absorbance was in IgM to the whole vaccine only. mM b-ME (Sigma) in Tris-buffered saline (25 mM Tris, 126 mM
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NaCl, 2.6 mM KCl, pH 7.2), to yield a final serum dilution of 1:50 and a b-ME concentration of 150 mM, and incubated for 1 to pneumococcal polysaccharide. Murine MAbs with specih at 37ЊC. b-ME-untreated and b-ME-treated samples were ficity for human V H 1, V H 3, and V H 4 variable region determiadded to capsular polysaccharide-coated plates, and antibody nants were used in an antigen-based ELISA to detect antibodies binding was detected by ELISA using the anti-idiotypic MAbs and expressing gene sequences from these families among antibod- terminants recognized by the D12, 16.84, and B6 MAbs (P õ b-ME treatment of pre-and postvaccination sera. When pre-and postvaccination sera were treated with b-ME, there .01) (figure 1). The HIV-infected group manifested a significant increase in antibodies to capsular polysaccharides in the whole was a decrease in serum antibody binding to the capsular polysaccharides in the whole vaccine for all b-ME -treated samples vaccine that expressed the V H 3 determinant recognized by the 16.84 MAb only (P õ .01). There were no detectable antibodies ( figure 3 ). For the HIV-uninfected group, in both untreated and b-ME -treated samples, there was a significant postvaccination in either group expressing the V H 1 determinants recognized by the G6 and G8 MAbs. There was an increase in antibodies to increase in antibodies to capsular polysaccharides in the whole vaccine expressing the V H 3 determinants recognized by the capsular polysaccharides in the whole vaccine expressing the V H 4 determinant recognized by the MAb LC1 in the HIV-D12, 16 .84, and B6 MAbs (P £ .02) ( figure 3 ). For the HIVinfected group, there was a significant increase in antibodies uninfected group only (P õ .01, Sign test).
The HIV-uninfected group manifested a postvaccination inexpressing the determinant recognized by the 16.84 MAb in b-ME -untreated samples only (P Å .02) (figure 3), and there crease in antibodies to the capsular polysaccharides of serotype 8 expressing the determinants recognized by D12, 16.84, and was no significant increase in antibodies expressing the determinants recognized by the D12 or B6 MAb in either b-ME -B6 (P õ .01) and LC1 (P Å .03) and of serotype 4 (P õ .01) and serotype 23F (P Å .03) expressing the determinant untreated or b-ME -treated samples. The binding of antibodies to capsular polysaccharides in the whole vaccine expressing recognized by MAb D12. There was a borderline increase in antibodies to serotype 14 expressing the determinant recogdeterminants recognized by the LC1 MAb from both groups was less than two times the background absorbance of the nized by B6 (P Å .05). For the HIV-infected group, there was a borderline increase in antibodies to serotype 8 expressing the assay in b-ME -treated samples (data not shown). determinant recognized by D12 (P Å .05). All P values were determined with the Sign test. For both groups, there was no Discussion significant postvaccination increase in antibodies to serotypes 3, 6B, or 14 expressing V H 3 or V H 4 determinants, and there Our results show that human antibodies to pneumococcal capsular polysaccharides use V H 3 gene segments expressing were no detectable antibodies expressing V H 1 determinants or the V H 4 determinant recognized by the MAb 9G4 (data not the determinants recognized by the D12, 16.84, and B6 MAbs and that pneumococcal vaccination elicits significantly lower shown). Comparisons of overall antibody responses between the HIV-uninfected and HIV-infected groups revealed that the levels of V H 3-positive antibodies specific for pneumococcal capsular polysaccharides in HIV-infected persons. Decreased HIV-uninfected group had significantly greater V H 3-and V H 4-positive antibody responses to the following pneumococcal IgM responses to capsular polysaccharides in the whole pneumococcal vaccine have been reported previously for HIV-incapsular polysaccharides (figure 2): whole vaccine and serotypes 4 and 8 expressing the V H 3 determinants recognized by fected persons [12, 13, 27] , and our results confirm this observation. The HIV-infected subjects in our studies had no history the D12, 16.84, and B6 MAbs (P õ .01) and whole vaccine and serotype 8 expressing the V H 4 determinant recognized by of HIV-associated opportunistic infections and a mean prevaccination CD4 T cell count of 395/mL. Nevertheless, they had LC1 (P õ .01). P values were determined with the MannWhitney U test. tive antibody responses to pneumococcal vaccination than did not recruited by vaccination in the HIV-infected group. This may be because the necessary B cells are not present in suffi-HIV-uninfected persons (figures 1 -3). It has been proposed that HIV-associated depletion of D12-positive V H 3 B cells is cient number, although other factors may contribute to decreased V H 3-positive antibody responses. inversely proportional to the CD4 T cell count, being most apparent in those with clinical AIDS [10] . However, our data V H 3 gene segments are expressed in the early human immunoglobulin repertoire [35, 36] . The D12 and B6 MAbs recogimply there may be a failure to generate V H 3-positive B cell responses earlier in HIV infection than suggested by a previous nize V H 3 determinants rearranged to k-, l-, m-, g-, and a-heavy and light chains, which are found on multiple V H 3 segments, report of depletion of D12-positive B cells in persons with AIDS [10] . This scenario is consistent with the clinical observaincluding DP35, DP40, 8-1B, DP42, DP46, DP49, DP50, and DP54 [24] . Antibodies to capsular polysaccharides in the whole tion that increased susceptibility to pneumococcal infection and impaired vaccine responses can occur early in the course of vaccine and serotype 8 expressed the determinants recognized by all three MAbs, but antibodies to serotypes 4 and 23F only HIV infection [1, 19, 30] .
The murine MAbs used for our studies have traditionally expressed the determinants recognized by the D12 MAb. This supports the concept that antibodies to different capsular polybeen referred to as ''anti-idiotypic'' antibodies, because of their reactivity with variable region determinants of human saccharides may be derived from different subsets of V H 3-positive antibody-producing B cells. Antibodies to serotype B rheumatoid factors [24] . More recently, it has been stated that rather than identifying cross-reactive idiotypes within antibodyNeisseria meningitidis and vaccine-elicited antibodies to H. influenzae type b are derived from DP50 [37 -39] . We found binding sites, these reagents recognize epitopes of germline V H genes, or ''isotypic'' determinants that are indicative of gene that antibodies to pneumococcal capsular polysaccharides reacted with the MAbs recognizing V H 3 determinants in the folusage [31] . Although reagents to detect the other V H families were not available, the V H 1, V H 3, and V H 4 families represent lowing order: D12 ú 16.84 ú B6. Naturally occurring rheumatoid factor antibodies can express the same determinants [24] , nearly 90% of the circulating V H repertoire [32, 33] . Our findings support the conclusion that vaccine-elicited antibodies to although the predominant reactivity of pneumococcal capsular polysaccharide antibodies with MAb D12 is unique compared pneumococcal capsular polysaccharides are derived from V H 3 and restricted in their gene usage. The V H 1 determinants recogto monospecific autoantibodies [24, 40] . Observations of shared V H gene usage among antibodies to capsular polysaccharides nized by the G6 and G8 MAbs and the V H 4-associated determinant recognized by the 9G4 MAb are not expressed by antibodsuggest they might be generated from restricted subsets of B cells producing naturally occurring antibodies. This is consisies specific for pneumococcal capsular polysaccharides. Our observation that prevaccination V H 3-positive antibodies bind tent with proposals that cross-reactive antibodies establish immunity to encapsulated pathogens [41] and that antibody rethe capsular polysaccharides in pneumococcal vaccine supports the concept that preimmune antibodies may be derived from sponses to polysaccharide vaccines have characteristics suggesting that they may represent recall responses [4, V H 3. Since the levels of antibodies to polysaccharides can persist for years [34] , and prevaccination V H 3 expression was 42 -44] . but it is presumed that they bind in framework regions rather than antigen-binding sites [50] . The binding site of SpA is capsular polysaccharides is associated with a specific k light chain idiotype. Polyreactive naturally occurring autoantibodies reportedly located in framework regions, although changes in complementarity-determining region 2 (CDR 2) have been imexpress the V H 4 determinant recognized by LC1 [48] , providing further evidence that a subset of B cells encoding naturally plicated in decreased binding to SpA [51] . Therefore, somatic mutation in either CDRs or framework regions might alter the occurring antibodies may contribute to the antibody repertoire that binds to capsular polysaccharides of S. pneumoniae. While binding of the anti-idiotypic MAbs; however, determining the role that affinity maturation plays in the generation of antibodthere is decreased B cell expression of the determinant recognized by D12 [10] , there is increased expression of V H 1 gene ies that do not bind to the V H 3 anti-idiotypic MAbs must await further specificity and structural studies. The most immunosegments in HIV-infected patients [49] . Depletion of B cells expressing the determinants recognized by the LC1, B6, and genic capsular polysaccharides in our HIV-uninfected subjects were serotypes 4 and 8 (table 1) , and these were also the 16.84 MAbs has not been reported; however, our data that antibodies expressing the determinants recognized by these serotypes that elicited the greatest D12-positive antibody responses (figure 2). We cannot exclude the possibility that the MAbs are markedly decreased in HIV-infected subjects make it logical to suggest the hypothesis that B cell precursors exmagnitude of D12-positive antibody responses is associated with capsular polysaccharide immunogenicity, but serotype 3 pressing these determinants may also be expressed at a lower frequency in HIV-infected persons. capsular polysaccharide, which is usually immunogenic [25], did not elicit a V H 3-positive antibody response in our subjects. Antibodies to the capsular polysaccharides of serotype 3 and 14 have been reported to be derived from V H 3 gene segments Postvaccination V H 3-positive antibodies to pneumococcal capsular polysaccharides manifested decreased, not undetect- [7, 42] . In this study, vaccine-elicited antibodies to the capsular polysaccharides of serotypes 3, 6B, and 14 did not express any able, binding after treatment with b-ME. This suggests that the V H 3-positive antibody response consists of both IgM and of the V H 3-associated idiotypes we examined, although there was a trend toward expression of the determinant recognized IgG. However, the fact that there was a significant reduction in antibody binding after b-ME treatment of postvaccination by the B6 MAb for antibodies to serotype 14. The size of our Binding of BME-treated and untreated antibodies to capsular polysaccharides in whole vaccine is depicted on y axis as absorbance (OD 405nm) detected with murine anti-idiotypic monoclonal antibodies D12, 16.84, B6, and LC1. Antibodies expressing determinant recognized by monoclonal antibody LC1 were undetectable after treatment of samples with BME and are not shown. Absorbances for persons in HIV-infected group were õ2 times background of assay for BME-treated samples detected with antibody 16.84 and BME-treated and -untreated samples detected with antibody B6 and are not shown. Data were obtained by ELISA using whole vaccine -coated plates. * P Å .02, comparing pre-and postvaccination BME-untreated and BME-treated samples in both groups using Sign test. sera only from the HIV-uninfected group supports the concept pneumococcal vaccine -elicited antibodies to clinically important serotypes, and this is associated with decreased antithat vaccination elicits VH3-positive IgM in this group. This is consistent with our findings that the HIV-uninfected group body responses to pneumococcal vaccine. Our finding of decreased expression of V H 3-associated idiotypes by the HIVhad significantly greater IgM responses to vaccination than did the HIV-infected group and a greater number of IgM respondinfected group may represent a quantitative or qualitative defect, or both. Either a deficiency of antibody-producing B cells ers (table 1) . Nevertheless, our data suggest that D12-positive antibodies are not restricted to IgM, because the HIV-uninexpressing V H 3 determinants or a generalized inability to stimulate B cells bearing specific V H 3 determinants could translate fected group mounted a D12-positive response to serotype 23F but did not manifest an IgM response to this serotype; the HIVinto impaired production of antibodies to capsular polysaccharides of S. pneumoniae. It remains to be established if dimininfected group only manifested an IgG response to serotype 8 but demonstrated a trend toward a D12-positive response to ished responses of HIV-infected persons to vaccines consisting of either protein or polysaccharide antigens [1] are attributable this serotype; and b-ME -treated sera from the HIV-uninfected subjects also demonstrated a significant increase in capsular to generalized, or specific, B cell defects. However, our data provide the first evidence to support the hypothesis that HIVpolysaccharide -specific V H 3 antibodies (figure 3). The HIVinfected group may have generated 16.84-positive IgM to capassociated depletion of B cells expressing specific V H 3 determinants [10, 49] may result in impaired antibody responses to sular polysaccharides in the pneumococcal vaccine that we did not examine individually, but they had significantly lower pneumococcal infection and/or vaccination. Much remains to be learned about the regulation of human antibody responses overall IgM-and VH3-positive antibody responses than did the HIV-uninfected group.
to capsular polysaccharides. Nevertheless, if antibodies to capsular polysaccharides can only be derived from restricted subOur data show that compared with HIV-uninfected persons, HIV-infected persons manifest lower levels of V H 3-positive sets of B cells that are deficient in HIV-infected persons, new
